Pfizer, which has struggled to find a follow-up to its blockbuster anticholesterol drug Lipitor, has stopped work on bococizumab, a cholesterol-lowering agent in Phase III clinical trials.

The firm cites efficacy and safety concerns as well as a “market landscape” unfavorable to new drugs in the category.

press release
article in C&EN